Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Meeks on the Genomics of Bladder Cancer

September 26th 2018

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the genomics of bladder cancer.

Dr. O'Donnell on the Evolution of Immunotherapy in Metastatic Bladder Cancer

September 25th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the evolution of immunotherapy in metastatic bladder cancer.

Dr. Sweis on Immunotherapy in Genitourinary Cancer

September 22nd 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Dr. Steinberg on BCG Progression in Non-Muscle Invasive Bladder Cancer

September 22nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses bacillus Calmette-Guérin (BCG) progression in non-muscle invasive bladder cancer (NMIBC).

Dr. Sonpavde on Remaining Questions With Immunotherapy in Bladder Cancer

September 19th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer.

FDA Approval Sought for Erdafitinib in Urothelial Carcinoma

September 19th 2018

A new drug application has been submitted to the FDA for erdafitinib for the treatment of patients with locally advanced or metastatic urothelial carcinoma and FGFR genetic alterations whose tumors progressed following chemotherapy.

Dr. Van Veldhuizen Discusses Combination Therapy in RCC

September 19th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.

Dr. Singh on the Role of Chemotherapy in Bladder Cancer

September 18th 2018

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.

Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCC

September 15th 2018

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the frontline approval of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic renal cell carcinoma (RCC).

Dr. Grivas on Combination Strategies in Genitourinary Cancer

September 13th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination strategies in genitourinary cancer.

Combinations Poised to Carry Clinical Benefit in RCC

September 13th 2018

Bradley McGregor, MD, discusses the impact of combination therapies on the treatment landscape and highly anticipated studies in renal cell carcinoma.

Dr. Ho on Managing Immune-Related AEs in Kidney Cancer

September 11th 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.

Dr. McGregor on Whether Patients Need Frontline Combinations in RCC

September 11th 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Avelumab/Axitinib Combo Improves PFS in Frontline RCC

September 11th 2018

Combining the PD-L1 inhibitor avelumab with the VEGF inhibitor axitinib significantly improved progression-free survival compared with sunitinib in treatment-naïve patients with advanced renal cell carcinoma, according to findings from the phase III JAVELIN Renal 101 study.

Dr. Gupta Discusses Combination Immunotherapy in RCC

September 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses combination immunotherapy in renal cell carcinoma.

Dr. Figlin Discusses the Future of Kidney Cancer Treatment

September 10th 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.

Sharma Stresses Importance of Refining Immunotherapy in GU Cancers

September 10th 2018

Padmanee Sharma, MD, PhD, shares her insight on the current state of immunotherapy in the treatment of patients with genitourinary cancers.

Dr. Van Veldhuizen on Frontline Immunotherapy for Kidney Cancer

September 7th 2018

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Dr. Agarwal on Next Steps in Kidney Cancer

September 7th 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the next steps in the kidney cancer paradigm.

Dr. Balar Discusses Study of Immunotherapy Combination in Bladder Cancer

September 6th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses a study of an immunotherapy combination in bladder cancer.